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Abstract
Brief measures to assess and monitor pain in cancer patients are available, but few head-to-head 
psychometric comparisons of different measures have been reported. Baseline and 3-month data 
were analyzed from 274 patients enrolled in the Indiana Cancer Pain and Depression (INCPAD) 
trial. Participants completed the Brief Pain Inventory (BPI), the PEG (a 3-item abbreviated version 
of the BPI), the short form (SF)-36 pain scale, and a pain global rating of change measure. The 
global rating was used as the criterion for standardized response mean and receiver operating 
characteristic curve analyses. To assess responsiveness to the trial intervention, we evaluated 
standardized effect size statistics stratified by trial arm. All measures were responsive to global 
improvement, discriminated between participants with and without improvement, and detected a 
significant intervention treatment effect. Short and longer measures were similarly responsive. 
Also, composite measures that combined pain severity and interference into a single score (BPI 
total, PEG, SF-36 pain) performed comparably to separate measures of each domain (BPI severity 
and BPI interference).
Perspective—Pain measures as brief as 2 or 3 items that provide a single score are responsive in 
patients with cancer-related pain. Ultra-brief measures offer a valid and efficient means of 
assessing and monitoring pain for the clinical management as well as research of cancer-related 
pain.
Keywords
Cancer; pain; measures; assessment; diagnosis; psychometrics
Pain is one of the most prevalent symptoms in patients with cancer, experienced by one-
third to two-thirds of all patients at some point during their illness.54 Pain can occur in all 
phases of cancer and may be caused by the tumor itself, diagnostic or therapeutic 
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procedures, or cancer treatment.43,44 Cancer-related pain has a major adverse impact on 
functional status and quality of life25,38,43,51,57 and, moreover, is undertreated in a 
substantial proportion of patients.10,15,47 A national survey of a geographically 
representative sample of medical oncologists in the U.S. found that 2 of the greatest barriers 
to optimal cancer pain management were patient reluctance to report pain and inadequate 
assessment of pain by physicians and nurses.2 This survey also revealed inadequate training 
in pain management, poor treatment decisions in simulated cases, and low referral rates to 
pain or palliative care specialists.
Valid and efficient ways of assessing pain are essential to optimize detection, monitoring, 
and management.34 Multidimensional approaches to assessing pain are recommended for 
clinical trials and other types of research.13,14 In clinical practice, however, brief and simple 
measures may be more desirable. Krebs et al31,33 have found that ultra-brief pain measures 
that yield a single composite score may be comparable to longer, multidimensional measures 
for evaluating and treating chronic noncancer pain. Whether this is also true for cancer-
related pain, however, is not known. Despite literature reviews and the convening of expert 
groups, there is not yet a consensus on the optimal tool for assessing pain in cancer 
patients.5,19,21,23,26,28
The Indiana Cancer Pain and Depression (INCPAD) study, a randomized clinical trial 
implemented with patients who had different types and phases of cancer, tested a 12-month 
telephone care management intervention to decrease pain and/or depression.37 The INCPAD 
trial demonstrated moderate pain improvement in the intervention group compared to the 
usual-care group (P < .001).39 The pain measures that were serially administered in 
INCPAD included the Brief Pain Inventory (BPI), the 3-item PEG scale (an abbreviated 
version of the BPI), and the 2-item Short-Form (SF)-36 pain scale. While the BPI is the 
most commonly used measure for assessing both pain severity and interference in adults 
with cancer and the SF-36 pain scale is a frequently used composite pain measure, there is a 
limited amount of research doing head-to-head psychometric comparisons of these or other 
pain measures in patients with cancer.26 Such comparisons are important for researchers in 
selecting measures for studies where pain is either a primary or secondary outcome, and for 
clinicians in choosing a measure they can use in practice to monitor response to pain 
treatments and to adjust therapy as needed. Factor analysis of brief and longer pain measures 
in a small Italian study of patients with cancer-related pain revealed a high degree of 
association among pain dimensions as well as a single factor explaining most of the different 
scales variability.9 Limitations of this study included its small sample size (n = 53) and the 
inclusion of some measures infrequently used in clinical research and practice.
One important aspect of a measure’s validity is responsiveness, the ability to detect a 
meaningful change in a clinical state. Responsiveness, also referred to as sensitivity to 
change, can be assessed in several ways. In this paper, we therefore compare the 
responsiveness of these 3 measures to cancer-related pain over 3 months by assessing the 
performance of the measures in 1) differentiating (using standardized response means) 
between subgroups of patients who report global pain improvement, lack of change, or 
worsening over 3 months; 2) discriminating (using receiver operating curve [ROC] analysis) 
between patients who did and did not report improvement of their pain at 3 months; and 3) 
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detecting (using standardized effect sizes) an intervention treatment effect, as well as 
assessing whether the treatment effect differed between depressed and nondepressed 
patients.
Methods
Participant Enrollment
The design and baseline participant characteristics in the INCPAD study have been 
published elsewhere, including participant enrollment and follow-up.37,39 Briefly, patients 
with cancer-related pain and/or depression were recruited from 16 urban and rural outpatient 
oncology clinics. Potential participants were patients who had moderately severe cancer-
related pain (a BPI worst-pain severity score ≥6), or depression (a Patient Health 
Questionnaire 9-item depression scale [PHQ-9] score ≥0, with depressed mood and/or 
anhedonia). Cancer-related pain had to be in the region of the primary tumor or cancer 
metastases and/or present after the onset of the cancer treatment. Patients with cancer-related 
pain had to have tried at least 1 analgesic but still be experiencing pain. The study excluded 
those who did not speak English, had moderately severe cognitive impairment, had 
schizophrenia or other psychoses, had a disability claim currently being adjudicated for pain, 
were pregnant, were in hospice care, or had preexisting pain conditions unrelated to cancer.
A total of 405 participants with depression, cancer-related pain, or both were enrolled in the 
INCPAD trial. For this secondary analysis, data from 274 participants who had cancer-
related pain (with or without depression) were analyzed: 137 in the intervention group and 
137 in the usual-care group. These 274 participants were enrolled from a group of 444 
patients who met all entry criteria for cancer-related pain, thus yielding an enrollment rate of 
62% of potentially eligible patients. The intervention group received centralized telephone 
care management (telecare) focusing on optimizing medications to treat their cancer-related 
pain and/or depression, while the usual-care group received care by their oncologists without 
attempts by study personnel to influence their pain and/or depression treatment unless a 
psychiatric emergency arose. Compared to the usual-care group, patients in the telecare 
intervention group had significantly greater pain improvement as assessed by the primary 
outcome of BPI pain severity (effect sizes of .36, .67, .46, and .39 at 1, 3, 6, and 12 months, 
respectively, P < .001).39
Outcome Assessment
Research assistants who conducted the phone interviews to collect data at baseline and 
follow-up were blinded to group assignment. Medical record reviews from the oncology 
practice were performed during the study. The study was approved by the institutional 
review boards at Indiana University and Community Hospital.
We assessed responsiveness of the following pain outcome measures:
• The BPI has been validated as a measure of chronic pain in cancer and other 
clinical populations.7,8,31 The BPI includes 4 items that assess the intensity of pain 
currently and at its least, worst, and average during the past week (rated from 0, 
“no pain,” to 10, “pain as bad as you can imagine”). An additional 7 items assess 
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pain-related functional interference (rated from 0, “does not interfere,” to 10, 
“interferes completely”). We assessed responsiveness of the 4-item BPI severity 
and 7-item BPI interference scales, as well as that of a BPI total score that includes 
all 11 items. For each scale, the total score is the average of all items (range, 0–10), 
where a higher score indicates worse pain.
• The PEG pain scale is a 3-item abbreviated scale of the BPI that includes 1 
intensity item and 2 interference items (Pain intensity during the past week, pain 
interference with Enjoyment of life, and pain interference with General activity).33 
Like the BPI, the total score is the average of all items (range, 0–10).
• The SF-36 pain scale is a validated subscale of the Medical Outcomes Study SF-36 
questionnaire.45,56 It includes 2 items, one that assesses intensity of pain (scale 
range: 1, “none,” to 6, “very severe”) and one that assesses how much pain has 
interfered with work (scale range: 1, “not at all,” to 5, “extremely”) over the past 4 
weeks. Responses are transformed into a 0 to 100 score, where a lower score 
indicates worse pain.
We used a patient-reported retrospective global rating of change as the reference standard 
for change in pain.16,31 At 3 months, participants were asked, “Overall, since starting the 
study, would you say your pain is worse, about the same, or better?” Those who reported 
their pain was better were asked a second question, “How much better is your pain?” with 
the following response options: a little, somewhat, moderately, a lot, or completely better.
Other study measures used in our analyses include depression severity as assessed by the 
Hopkins Symptom Checklist 20-item depression scale (HSCL-20); medical comorbidity as 
assessed by an 8-disease checklist; and the Socioeconomic Disadvantage (SED) index, a 3-
point composite score that assigns 1 point each for low education, low income, and 
unemployment.40
Analysis
Baseline and 3-month data are used for the analyses in the present paper because the most 
intense phase of the INCPAD pain intervention as well as the greatest change in pain scores 
occurred during the initial 3 months of the trial. Moreover, this period was least affected by 
attrition due to death, disease progression, drop-out, or loss to follow-up that had occurred 
by 6 and 12 months. For the analyses that required only baseline data, we used data from all 
274 participants enrolled with pain, whereas responsiveness analyses included the 230 
participants with data available at both baseline and 3-month follow-up.
We calculated standardized response means (SRM) and ROC curves to analyze 
responsiveness. Retrospective patient-reported global ratings of change are the most 
common anchors used for responsiveness analysis in pain research; in this study, we used 
the 3-month global rating of change. Additionally, to assess responsiveness of each measure 
to group differences in the randomized trial, we evaluated standardized effect size (SES) 
statistics stratified by trial arm (intervention and control). Statistical analyses were 
performed using SAS v.9.1 (SAS Institute Inc, Cary, NC).
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Standardized Response Means—The SRM is an effect size index that includes 
response variance in the denominator.29 SRM values are unitless and therefore directly 
comparable between measures. Effect sizes of .2 are generally considered small, .5 are 
moderate, and .8 are large.30 We categorized participants according to their 3-month global 
rating of change (worse, same, or better). For each measure, we calculated the SRM (3-
month mean change score/SD of change) stratified by category of change.41 A bootstrapping 
procedure was used to derive 95% confidence intervals (CIs) for the SRM.42
Area Under the ROC Curve—Area under the ROC curve (AUC) values are interpreted 
as the probability that a measure correctly discriminates between patients who are improved 
and those who are not; the possible range of values is .5 (no ability to discriminate) to 1.0 
(perfect ability to discriminate). Because ROC analysis requires a binary outcome, we 
classified patients who stated that their pain was “better” as improved and those who stated 
that their pain was “the same” or “worse” as not improved.31 The rationale for collapsing the 
latter 2 categories is that clinicians would typically consider patients who stay the same as 
treatment failures (ie, nonresponders), because the goal of treatment is to make patients 
better rather than have their pain remain unchanged or worsen. We calculated the AUC for 
each outcome measure using improvement on the 3-month global rating of change as the 
anchor.12 We secondarily calculated AUCs for a moderate improvement threshold (at least 
“moderately” better).14,31 Finally, we conducted pairwise comparisons between pain 
measures to determine if they were significantly different in their ability to detect 
improvement.11
Standardized Effect Sizes by Randomized Trial Arm—To assess measures’ 
responsiveness to intervention effects, we evaluated SES according to trial arm (telecare 
intervention versus usual care). We calculated change scores (3 months minus baseline) and 
standardized effect sizes (SES = [intervention group change minus usual-care group 
change]/SD of pooled change scores)4 to assess whether measures performed similarly 
among participants in the trial overall as well as in the depressed and nondepressed 
subgroups, stratified by intervention group.
Effect of Depression on Responsiveness of Pain Measures—We first examined 
whether depression status affected responsiveness in a logistic regression model where the 
dependent variable was patient global rating of pain change (improved versus same/worse), 
the predictor variable was depression as a categorical variable (yes/no) defined by our 
PHQ-9 thresholds, and covariates were baseline pain severity, age, sex, race, SED index, 
medical comorbidity, and treatment arm (intervention versus control). Second, we ran the 
same model using as the predictor variable baseline depression severity as a continuous 
variable (HSCL-20 score). Third, we also examined whether responsiveness of each of the 
specific pain scales varied with depression status by running linear regression models with 
the 3-month change score on the pain scale as the dependent variable, baseline depression 
status as a categorical (yes/no) predictor variable, and adjusting for the same covariates.
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Results
Patient Characteristics
The baseline characteristics of the participants are shown in Table 1. Two-thirds of the 
participants were female, 77% were white, and 65% had both cancer-related pain and 
depression upon enrollment in the study. Their mean age was 58 years, with a range from 23 
to 85 years. At baseline, they reported moderate pain intensity on the BPI scale. Two-thirds 
of the patients had comorbid depression. As previously reported, randomization resulted in 
intervention and usual-care groups that were similar in all baseline characteristics.37 
According to the pain global rating of change, 51 (22.2%) of the 230 participants were better 
at 3 months, 72 (31.3%) were about the same, and 107 (46.5%) were worse.
Internal Reliability and Interscale Correlations
The pain scales had good internal reliability with a Cronbach’s alpha of .79 for the BPI 
severity scale, .89 for the BPI interference scale, .89 for the BPI total scale, .69 for the PEG 
scale, and .73 for the SF-36 pain scale.
Table 2 shows the correlations of the pain scales with one another at baseline and 3 months. 
All scales were strongly correlated at both timepoints, with, as expected, the highest 
correlations for BPI-related scales that had some items in common.
Standardized Response Means
Table 3 shows SRM values for patients classified as worse, the same, and better according to 
their 3-month global rating of change. Overall, effect sizes for measures were similar within 
each category of change. Participants with improved pain according to the global rating had 
moderate-to-large improvement in scores on each scale. Also, SRMs significantly differed 
(P < .001) between the better, same, and worse groups for each of the scales, except for the 
same and worse groups on the SF-36 pain scale.
Area Under the ROC Curve
Table 4 shows the AUC for each measure, first using any improvement on the global rating 
as the reference standard and second using moderate improvement on the global rating. 
Overall, AUC values for the measures were similar; most AUC values had fair 
discriminatory ability (range, .73–.81). There were no statistically significant differences 
between the AUCs of any of the measures in detecting either any improvement or moderate 
improvement. The responsiveness of each measure to the presence of any improvement was 
about as good as its responsiveness to moderate improvement, and shorter measures (PEG 
and SF-36 pain) performed similarly to longer measures.
Standardized Effect Sizes
As shown in Table 5, all measures detected a moderate intervention effect, with relatively 
similar SES for the scales, ranging from .43 to .58 in the overall sample. SES were generally 
larger in the nondepressed than in the depressed subgroup, consistent with the greater 
difficulty of treating pain in depressed patients.1
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Effect of Depression on Responsiveness of Pain Measures
In logistic regression models, baseline depression status measured as either a categorical or 
continuous variable did not influence patient global rating of change (improved versus same/
worse) in unadjusted or adjusted models. The only covariates that resulted in a greater 
likelihood of improvement were being assigned to the intervention arm and having fewer 
comorbid medical diseases. Likewise, linear regression models demonstrated that the 
magnitude of improvement as assessed by 3-month change scores for each of the specific 
pain scales was greater in individuals assigned to the intervention arm as well as those with 
more severe pain at baseline but was not influenced by depression status.
Discussion
Summary of Measures
Our study has several important findings. First, all 3 pain measures (BPI, PEG, and SF-36 
pain) performed similarly in detecting improvement and in differentiating outcome 
categories (better, same, worse) by 2 types of responsiveness analyses: SRM and ROC. 
Second, the measures were comparable in detecting a moderate between-group (intervention 
versus control) treatment effect in the randomized trial. Third, composite measures (BPI 
total, PEG, and SF-36 pain) performed as well as the BPI subscales that measure pain 
severity and pain interference separately. Fourth, shorter scales (PEG and SF-36 pain) 
consisting of 2 or 3 items were nearly as responsive as longer measures.
There are several important reasons that global rating of change was selected as the standard 
for comparing the responsiveness of pain measures. First, comparing the responsiveness of 
multiple different pain measures required using a single method independent of the pain 
measures themselves to classify patients into the 3 groups of improved, unchanged, and 
worse. Had longitudinal changes on the pain measures themselves been used to classify 
patients, there would have been differing numbers of patients in the 3 groups for each of the 
measures, and it would have been impossible to do comparisons across measures. Second, 
global rating of change is an anchor-based method of assessing change, whereas longitudinal 
change on a continuous pain measure is a distribution-based method of assessing change. 
Both methods contribute important but complementary information in assessing 
responsiveness, and using an anchor-based standard is a well-accepted approach to compare 
responsiveness of distribution-based measures.16,49,58 Third, global rating of change is one 
of the most commonly used anchor-based methods for assessing responsiveness in pain 
research.14,31 Of note, the results in Table 3 provide empiric support for the use of global 
rating of change as the independent standard because the SRMs for each pain measure 
discriminated between the 3 subgroups of patients who globally rated their pain as better, the 
same, or worse.
The pain scales showed a moderate between-group treatment effect size in patients with and 
without comorbid depression (Table 5). This is a salient finding given the frequency of 
comorbid depression in cancer patients with pain and the additive adverse effects of 
depression and pain on quality of life and functional status.38 The treatment effect size, 
although still moderate in magnitude, was somewhat less in depressed patients compared to 
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nondepressed patients (Table 5), which is consistent with previous research showing that 
pain response to therapy may be negatively influenced by depression.1,35,59 The fact that a 
reasonable treatment effect was nonetheless demonstrated in the depressed group may in 
part have been due to the design of the INCPAD intervention, which provided treatment for 
depression as well as pain in patients suffering from both symptoms.37 Importantly, our 
multivariable models did not find baseline depression status measured as either a categorical 
or a continuous variable to be a confounder of patient-reported global improvement in pain 
or in change scores on any of the specific pain measures. Thus, the smaller treatment effect 
sizes seen for depressed compared to nondepressed patients more likely represents the 
greater difficulty in treating pain in depressed patients rather than a biasing influence of 
depression on pain assessment. Future studies incorporating differential item functioning 
analyses to further explore the psychometric effects of depression may be worthwhile.
Translating Results into Practice
Pain screening, assessment, and monitoring of treatment response are core quality indicators 
for management of cancer-related pain.19 However, as recently noted by Hjermastad et al,22 
“Pain is still not routinely measured in cancer clinical practice. This may be because most 
tools are too long and cumbersome for patients and clinicians to use.” For example, 2 of the 
most commonly used measures in research of cancer-related pain have been the McGill Pain 
Questionnaire and the BPI.5,25,48 However, the length and complexity of the McGill Pain 
Questionnaire in particular makes it less feasible for clinical practice, in contrast to the 
shorter and simpler BPI. Indeed, numerical (0–10) rating scales (of which the BPI and PEG 
are exemplars) have been shown to have higher discriminatory capability than verbal rating 
scales in distinguishing differing levels of pain3 and are increasingly being recommended by 
experts in palliative care.23,28
Our previous study of primary care patients with noncancer musculoskeletal pain also 
showed a similar responsiveness of the PEG, BPI severity, BPI interference, and BPI total 
scales.31 In that study, the SF-36 pain scale appeared somewhat less responsive. It has been 
recommended that pain severity and pain interference are distinct dimensions, both of which 
should be assessed in pain research.13,14 Indeed, a systematic literature review of pain 
assessment scales for patients with advanced cancer receiving palliative care revealed that 
pain severity and interference accounted for the majority of items on the scales.24
The BPI total, PEG, and SF-36 pain scales do include both severity and interference items 
but combine them into a single composite score. This may be attractive in clinical practice 
so that providers need not interpret and monitor 2 separate numbers but rather can follow a 
single score. In particular, separate scores may complicate decision-making if severity and 
interference ratings are discordant. Of the 2 dimensions, the interference/functional 
impairment associated with pain may be of somewhat greater importance than pain severity 
alone.53,55 In this regard, the BPI total and PEG assign approximately a 2:1 weight to 
interference items, which constitute 7 of the 11 items in the BPI total and 2 of the 3 items in 
the PEG. Further evidence in support of a composite score is provided by a comparison of 6 
pain measures in 53 cancer patients that found that a single factor explained most of the 
different scales’ variability.9 Although a single score may be especially attractive for clinical 
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practice, the fact that composite scores have responsiveness similar to separate severity and 
interference scales may also be useful in choosing a primary outcome in clinical trials.39,52
Brevity is another desirable feature of measures intended for clinical practice. For example, 
the validity of ultra-brief measures (2–4 items) for depression and anxiety has been 
established.36,46 The fact that responsiveness of the 3-item PEG is similar to its longer 
parent measure for both cancer-related pain in our INCPAD trial as well as noncancer pain 
in a previous trial31 suggests a promising role for ultra-brief pain measures as well. 
Currently, a single-item assessment of current pain on a 0 to 10 scale has been promulgated 
as part of the “pain as the fifth vital sign” initiative advocated by The Joint Commission and 
other health organizations. However, this single item was initially developed to assess acute 
pain in hospitalized patients, whereas studies of its performance in outpatients with chronic 
pain have demonstrated only modest accuracy in detecting clinically important pain.32 In 
this regard, the ultra-brief PEG may achieve an optimal balance between single-item and 
longer pain scales. The SF-36 pain scale is also brief but is more complicated to score 
(requiring transformation) and was less responsive than the PEG in a previous trial of 
noncancer pain.31 It is possible that the longer recall window for pain of the SF-36 pain 
scale compared to the PEG and BPI scales (past 4 weeks versus past 1 week) may partly 
account for its lower responsiveness in treatment trials.
Example Case
A 62-year-old man with newly diagnosed lung cancer and right chest wall pain reports a 
PEG score of 7, indicating a relatively high level of pain (1–3, 4–6, and 7–10 represent mild, 
moderate, and severe levels of pain, respectively). Initiation of opioid therapy reduced the 
PEG score to 3; however, a subsequent increase to 8 following thoracotomy required an 
escalation in opioid dose. After 4 weeks, nonopioid analgesic therapy was sufficient until 6 
months later when the cancer progressed and bony metastases developed. Long-acting 
opioids were initiated with the supplemental use of short-acting opioids for rescue pain. As 
the patient progressed to hospice care, localized radiotherapy for bone pain as well as higher 
doses of opioids were used in efforts to maintain the PEG score in the range of 3 to 5 as 
much as possible. To minimize unnecessary clinic visits, the patient’s PEG score was 
monitored at home using automated technology (either interactive voice-recorded phone 
calls or internet-based reporting) coupled with nurse calls for PEG scores that failed to 
improve or worsen or for treatment-related side effects or nonadherence.27
Study Limitations
Our study has several limitations. While its generalizability was enhanced by enrolling 
patients with a wide range of types and phases of cancer, the target population was oncology 
outpatients reporting pain rather than inpatients or patients receiving hospice care. The latter 
groups might require even more intensive monitoring and analgesic adjustments including 
more frequent assessment and special attention to breakthrough pain.6,21,50 A second 
limitation is the use of multiple comparisons between multiple measures. In this regard, the 
similar responsiveness we found for these same measures in a primary care population with 
noncancer pain is reassuring.31 A third limitation is a likely ceiling effect for worsening of 
pain in our study population. Participants with pain in INCPAD had pain of at least 
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moderate severity at baseline and, therefore, a more restricted range for pain to worsen. This 
may partly explain why change scores among those who reported improvement were larger 
in magnitude than change scores among those who reported worsening. However, it is also 
possible that there is greater concordance between anchorand distribution-based outcome 
measures (ie, measures based on recall of global change from a previous time point versus 
those that assess the present status of pain) in terms of assessing improvement compared to 
assessing worsening. To this end, the recommendation that both types of measures be used 
to assess the outcomes of pain treatments is warranted.13,14
Pain Measurement as One Component of Improving Cancer Pain Management
Although the availability of scales that are at once valid and ultra-brief is an important 
advance in the management of cancer-related pain, measurement alone is insufficient. By 
analogy, it has been established that simple screening for depression does not improve 
outcomes18 unless it is coupled with systems-based interventions that include regular 
monitoring and adjustments of treatment.17 Likewise, quality indicators for cancer-related 
pain include not only assessment but also patient education, adjustment of treatment to 
achieve adequate control, the use of multimodal treatments, and attention to function and 
side effects as well as pain intensity.19 Nonetheless, pragmatic scales are an essential 
component of the measurement-based care that is necessary for the optimal treatment of 
pain34 as well its concomitant psychological comorbidity.20
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Table 1
Baseline Characteristics of 274 Study Participants With Cancer-Related Pain
Baseline Characteristics Mean (SD)
Age 58.08 (10.54)
Socioeconomic Disadvantage (SED) index* 1.30 (.98)
Medical comorbidity (no. of diseases) 2.09 (1.68)
BPI pain severity score (0–10 scale) 5.22 (1.82)
BPI pain interference score (0–10 scale) 5.65 (2.56)
BPI total score (0–10 scale) 5.48 (2.08)
PEG total score (0–10 scale) 5.87 (2.24)
SF-36 pain score (0–100 scale) 31.7 (17.8)
N (%)
Group
  Intervention 137 (50.0)
  Control 137 (50.0)
Symptom
  Pain 96 (35.0)
  Pain and depression 178 (65.0)
Gender
  Male 93 (33.9)
  Female 181 (66.1)
Race
  White 212 (77.4)
  Black and others† 62 (22.6)
Marital status
  Married 130 (47.4)
  Unmarried 144 (52.6)
Type of cancer
  Breast 70 (25.6)
  Lung 53 (19.3)
  Gastrointestinal 51 (18.6)
  Lymphoma/Hematological 40 (14.6)
  Genitourinary 27 (9.9)
  Other 33 (12.0)
Phase of cancer
  Newly diagnosed 104 (38.0)
  Maintenance or disease free 110 (40.2)
  Recurrent or progressive 60 (21.9)
*
The SED index included variables of education (“less than high school” = 1 point), employment (“unemployed” or “unable to work due to health 
or disability” = 1 point), and income (“not enough” = 1 point).
†Other races constituted only 1.8% (n = 5) of the sample.
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Table 4
Area Under the ROC Curve (AUC) for Pain Measures in Detecting Improvement*
Accuracy For
Detecting Any
Improvement†
Accuracy For
Detecting Moderate
Improvement†
AUC‡ SE AUC‡ SE
BPI severity .783 .030 .809 .032
BPI interference .726 .035 .732 .040
BPI total .786 .030 .801 .033
PEG .742 .034 .754 .038
SF-36 pain .729 .033 .735 .037
*Calculated in the 230 study participants who completed both baseline and 3-month assessments.
†Any improvement ≥“a little better”; moderate improvement ≥“moderately better”.
‡AUC is probability of correctly discriminating between patients who have improved and those who have not. There were no statistically 
significant differences in pairwise comparisons of the AUCs between any of the pain measures in detecting either any improvement or moderate 
improvement. Likewise, within each measure, its AUC for detecting any improvement was not statistically different from its AUC for detecting 
moderate improvement.
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